Iżrael - Ingliż - Ministry of Health

dexcel ltd, israel - carvedilol - tablets - carvedilol 6.25 mg - carvedilol - carvedilol - treatment of symptomatic congestive heart failure. carvedexxon may be used as adjunct to standard therapy, but may also be used in those patients unable to tolerate an ace inhibitor, or those who are not receiving digitalis, hydralazine or nitrate therapy.

Iżrael - Ingliż - Ministry of Health

dexcel ltd, israel - carvedilol - tablets - carvedilol 12.5 mg - carvedilol - carvedilol - treatment of symptomatic congestive heart failure. carvedexxon may be used as adjunct to standard therapy, but may also be used in those patients unable to tolerate an ace inhibitor, or those who are not receiving digitalis, hydralazine or nitrate therapy.

Iżrael - Ingliż - Ministry of Health

dexcel ltd, israel - lercanidipine hydrochloride - tablets - lercanidipine hydrochloride 10.0 mg - lercanidipine - lercanidipine - mild to moderate essential hypertension.

Iżrael - Ingliż - Ministry of Health

dexcel ltd, israel - captopril - tablets - captopril 25 mg - captopril - captopril - -hypertensioncongestive heart failure-insulin dependent diabetic nephropathy in hypertensive and non hypertensive patients in cases where the serum creatinine level < 2.5 mg/dl.-improve survival following myocardial infarction in clinically stable patients with left ventricular dysfunction manifested as an ejection fraction less or equals to 40% and to reduce the incidence of overt heart failure and subsequent hospitalization for congestive heart failure in these patients.

Iżrael - Ingliż - Ministry of Health

dexcel ltd, israel - captopril - tablets - captopril 50 mg - captopril - captopril - -hypertensioncongestive heart failure-insulin dependent diabetic nephropathy in hypertensive and non hypertensive patients in cases where the serum creatinine level < 2.5 mg/dl.-improve survival following myocardial infarction in clinically stable patients with left ventricular dysfunction manifested as an ejection fraction less or equals to 40% and to reduce the incidence of overt heart failure and subsequent hospitalization for congestive heart failure in these patients.

Iżrael - Ingliż - Ministry of Health

dexcel ltd, israel - ciclosporin - capsules - ciclosporin 100 mg - cyclosporin - cyclosporin - prophylaxis of organ rejection in kidney liver heart allogenic transplants in conjunction with corticosteroids. may also be used in the treatment of chronic rejection in patients previously treated with other immuno-suppressive agents. bone marrow transplantation. endogenous uveitis. severe psoriasis above age 16 that did not respond to other treatment. atopic dermatitis in adults only up to 8 weeks for severe cases in which conventional therapy is ineffective or inappropriate. rheumatoid arthritis: severe cases in which standard treatments are ineffective or inappropriate. nephrotic syndrom type mcd (minimal change disease) in cases where conventional therapy has failed.

Iżrael - Ingliż - Ministry of Health

dexcel ltd, israel - ciclosporin - capsules - ciclosporin 25 mg - cyclosporin - cyclosporin - prophylaxis of organ rejection in kidney liver heart allogenic transplants in conjunction with corticosteroids. may also be used in the treatment of chronic rejection in patients previously treated with other immuno-suppressive agents. bone marrow transplantation. endogenous uveitis. severe psoriasis above age 16 that did not respond to other treatment. atopic dermatitis in adults only up to 8 weeks for severe cases in which conventional therapy is ineffective or inappropriate. rheumatoid arthritis: severe cases in which standard treatments are ineffective or inappropriate. nephrotic syndrom type mcd (minimal change disease) in cases where conventional therapy has failed.

Iżrael - Ingliż - Ministry of Health

dexcel ltd, israel - ciclosporin - capsules - ciclosporin 50 mg - cyclosporin - cyclosporin - prophylaxis of organ rejection in kidney, liver, heart allogenic transplants in conjunction with corticosteroids. may also be used in the treatment of chronic rejections in patients previously treated with other immunosuppresive agents. bone marrow transplantation. endogenous uveitis. severe psoriasis above age 16 that does not respond to other treatment . atopic dermatitis in adults only up to 8 weeks, for severe cases in which conventional therapy is ineffective or inappropriate. rheumatoid arthritis, severe cases when standard treatment is ineffective or inappropriate. nephrotic syndrome type mcd (minimal change disease) in cases where conventional therapy has failed.

Iżrael - Ingliż - Ministry of Health

dexcel ltd, israel - allopurinol - tablets - allopurinol 300 mg - allopurinol - allopurinol - management of patients with signs and symptoms of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis and/or nephropathy). management of patients with leukemia, lymphoma, and malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels. management of patients with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds 800 mg/day in male patients and 750 mg/day in female patients. therapy in such patients should be carefully assessed initially and reassessed periodically to determine in each case that treatment is beneficial and that the benefits outweigh the risks.

Iżrael - Ingliż - Ministry of Health

dexcel ltd, israel - allopurinol - tablets - allopurinol 100 mg - allopurinol - allopurinol - management of patients with signs and symptoms of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis and/or nephropathy). management of patients with leukemia, lymphoma, and malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels. management of patients with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds 800 mg/day in male patients and 750 mg/day in female patients. therapy in such patients should be carefully assessed initially and reassessed periodically to determine in each case that treatment is beneficial and that the benefits outweigh the risks.